Orion Biotechnology

Orion Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class immunotherapies based on novel recombinant chemokine analogs. Our goal is to significantly improve the health of populations affected by serious diseases in the fields of oncology, neuroinflammatory disorders, inflammatory bowel disease, HIV, and more. By leveraging our proprietary drug discovery platform, we are able to accelerate the identification and lead optimization of chemokine analogs and other small proteins. Our first biologic – OB-002 – is being developed to address critical unmet needs in oncology and multiple sclerosis indications and is currently in clinical trials for HIV prevention.